Awakn Life Sciences Corp. (954.F)

0,0515 -0,0005 (-0,96%) Ab 08:10AM CEST. Markt geöffnet.

Awakn Life Sciences Corp.

217 Queen Street West
Suite 301
Toronto, ON M5V 0R2
Canada

https://awaknlifesciences.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 6

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. George Scorsis	Co-founder & Chairman of the Board	N/A	N/A	1977
Mr. Anthony Tennyson	Co-founder, President, CEO & Director	164,03k	N/A	N/A
Mr. Jonathan James Held C.A., CPA, CA	Co-founder, CFO, Chief Business Officer & Secretary	102,52k	N/A	1986
Prof. David John Nutt DM, FMedSci, FRCP, FRCPsych, FSB, Ph.D.	Chair of Pre-Clinical & Clinical Advisory Board and Chief Research Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Awakn Life Sciences Corp., a biotechnology company, engages in the research, development, operation, and delivery of psychedelic therapeutics to treat addiction and other mental health conditions in North America and Europe. It develops AWKN-001, a novel medication-assisted treatments (MAT) consisting of racemic ketamine, delivered intravenously, and manualized relapse prevention cognitive behavioural therapy (CBT) which is in phase 3 trials to treat severe Alcohol Use Disorder (AUD); AWKN-002, a novel MAT consisting of a patent pending proprietary S–ketamine oral thin film, and manualized relapse prevention CBT to treat AUD; and MDMA/Zydis, an investigational medicinal product entactogen that acts as a releaser and reuptake inhibitor of serotonin, norepinephrine, and dopamine. The company has a collaboration agreement with the University of Exeter for exploring the use of ketamine-assisted therapy to treat Severe AUD. Awakn Life Sciences Corp. is headquartered in Toronto, Canada.

Corporate Governance

Awakn Life Sciences Corp.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.